Table 5.
Treatment of case-reported patients with ROHHADNET syndrome (IPD).
| Treatment | Total number of patients (n = 48) |
|---|---|
| Number of patients (%) | |
| Respiratory support | 21 (43.8%) |
| Mechanical ventilation | 20 (41.7%) |
| BIPAP | 7 (14.6%) |
| CPAP | 1 (2.1%) |
| Noninvasive mask | 1 (2.1%) |
| Tracheostomy | 6 (12.5%) |
| Steroids | 7 (14.6%) |
| Methylprednisolone | 2 (4.2%) |
| Steroid pulse therapy | 2 (4.2%) |
| Prednisolone | 2 (2.1%) |
| Dexamethasone | 1 (2.1%) |
| Fluid resuscitation | 4 (8.3%) |
| Intravenous immunoglobulins | 7 (14.6%) |
| Immunosuppressive agents | 7 (14.6%) |
| Rituximab | 5 (10.4%) |
| Cyclophosphamide | 6 (12.5%) |
| Other agents | |
| Antipsychotics | 3 (6.3%) |
| Desmopressin acetate | 2 (4.2%) |
| GH replacement | 2 (4.2%) |
| Anti-epileptics | 2 (4.2%) |
| Levothyroxine | 4 (8.3%) |
| Caffeine | 1 (2.1%) |
| Hypertensive medication | 1 (2.1%) |
| Procedure | 2 (4.2%) |
| Brain hypothermia | 1 (2.1%) |
| Tonsillectomy | 1 (2.1%) |
BIPAP: bilevel positive airway pressure; CPAP: Continuous Positive Airway Pressure; GH: growth hormone.